You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

19 Items
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer
Drugs Used:
pembrolizumab (Compassionate),
Updated
Jul 2019
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Drugs Used:
topotecan (Unfunded),
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Updated
Aug 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer
Drugs Used:
pembrolizumab (Compassionate),
Updated
Aug 2019
Cancer Type: Sarcoma, Ewing's, Soft Tissue     
Intent: Palliative
Feb 2018
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Updated
Aug 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab
Sep 2018
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line)
New Drug Funding Program
    Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Jan 2018
Cancer Type: Skin, Melanoma     
Intent: Adjuvant
Drugs Used:
pembrolizumab (Compassionate)
Jul 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Drugs Used:
pembrolizumab (Compassionate)
Jan 2018
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Palliative
Drugs Used:
pembrolizumab (Compassionate)
Feb 2018
Cancer Type: Genitourinary, Bladder / Urothelial     
Intent: Palliative
Drugs Used:
pembrolizumab (Compassionate)
Jul 2019